Science Sub-Journal: New Antibodies

The antibody was determined by a team from the Duke Human Vaccine Institute (DHVI) and tested in an animal model at the University of North Carolina at Chapel Hill

"This antibody may become a popular therapeutic drug," said Dr.

Haynes and DHVI's colleagues analyzed the blood of a patient infected with the SARS-cov-1 virus and a patient with new coronary pneumonia, and isolated the antibody

They found more than 1,700 kinds of antibodies.

Researchers at Duke University discovered 1,700 antibodies from these two individuals.

Further analysis found that one of the cross-binding antibodies is particularly effective-in addition to the two pathogens that infect humans, it can also bind to a variety of animal coronaviruses

Haynes said: "The position where this antibody binds to the coronavirus is conserved among many mutations and mutations

After isolating the antibodies, the DHVI team turned to researchers at the University of North Carolina with expertise in animal coronaviruses

They found both

Baric said: "These findings provide a template for the rational design of universal vaccine strategies that are resistant to variability and provide broad protection against known and emerging coronaviruses

Compared with animals that have not received antibody treatment, injection of this antibody after infection can reduce severe lung symptoms

"Therapeutic activity even if the mouse infection indicates that this may be a treatment deployed in the current influenza pandemic, but also storage to prevent future outbreaks or epidemics of the difficult spread of the virus," said David Martinez, Ph.

Martinez said: "This antibody can be used to prevent SARS-CoV-3 or SARS-CoV-4

Research leaders include Priamvada Acharya and Haynes, Baric and Alexandra Scha? They co-authored this article with Martinez

This project is partly funded by the National Institute of Allergy and Infectious Diseases and the National Institutes of Health (AI157155, U54 CA260543, AI149644, AI145687, AI158571, HHSN272201700036I, AI142596); North Carolina has a Federal Care Act fund; National Cancer Institute (5P30CA016086-41); National Institutes of Health and Department of Defense Duke Regional Biological Containment Laboratory (UC6AI058607, HR0011-17-2-0069); University of North Carolina and Duke University's North Carolina Policy Cooperation Laboratory Was funded by the North Carolina Convention

Journal Reference :

1. David R.